ITALY – Pisa. Hematopoietic stem cell collection center opens

The Pisa University Hospital has become part of the international network of hematopoietic stem cell transplant facilities (meaning they produce various blood components). The hospital was recently accredited by the Italian registry of bone marrow donors, which is part of the international network.

Pisa has become an important center for bone marrow collection for all potential donors in northwestern Italy.
On 20 April 2009, the first donation was carried out for a patient at the Udine University Hospital, and a second donation is being organized for a patient being treated at the Montpellier Hospital (France).

The hospital in Pisa received the prestigious recognition thanks to the positive results they have obtained over the past years in the hematology and oncology- hematology units.

Reblog this post [with Zemanta]

GREAT BRITAIN – Artificial type 0 blood thanks to embryonic stem cells

union jack
Image by steve p2008 via Flickr

After making news on several occasions, scientists may have made a definitive breakthrough, with the first possible transfusion using blood obtained from embryonic stem cells possibly coming within the next three years. The transfusion would be done with type O blood, which can be donated to any patient, and would be obtained by researchers using excess embryos from assisted fertilization. The project, which will be led by Marc Turner of Edinburgh University, will also receive contributions from the Transfusion and Transplant Service of the British National Health Service, as well as the same department and Scotland, and the Welcome Trust, a large charitable group for medical research. The story was reported by the Independent and immediately created controversy and distorted information.

“This isn’t just talk, this time it is a serious breakthrough, and the group behind the project is very serious,” said Professor Carlo Alberto Redi, the scientific director of the IRCCS (Hospital and Medical Treatment) Foundation of the San Matteo General Hospital in Pavia, commenting on the story. Redi emphasized that the capability for the regeneration of the hematopoietic progenitor cells in vitro is well-known and the time is right for real blood to be created, with the term artificial blood no longer appropriate. “When the term synthetic blood is used, people imagine silicone blood, when in reality, in all effects, this is real blood,” said Redi.

IT CANNOT REPLACE BLOOD DONATIONS

The blood that the British researchers plan to use in human treatments in the next three years will only “support and complement” blood donation. Giuseppe Novelli, a geneticist of the University of Rome Tor Vergata, commenting to Adnkronos Salute, was less optimistic. “This is only an announcement, and it seems premature to talk about a victory. This research is starting off well because it has millions in financing and is based on evidence that is very hopeful. But we are only talking about one piece of a very complex puzzle.”

The puzzle, in this case, is represented by the blood that runs through our veins and arteries, “made up of red and white blood cells, platelets, and plasma,” said Novelli. “It is a very complex liquid, which carries out an essential function in our body.” The British study which is currently being launched “is limited to red blood cells, which are certainly not able to resolve all of the problems with transfusions”. The British studies are also developing type O negative blood, a group that is able to donate to any patient without any risk of rejection. “This is blood that can be used, and is used, only in case of emergency.” Novelli continued to say that “the new blood will not be able to replace real blood donation, and I don’t want these announcements to inhibit people from donating blood, or make them underestimate the value or the importance blood donation”.

As for an estimate on how much time it will take to create a synthetic blood that will resolve all problems linked to a lack of donations, Novelli said: “I’m not a magician! Science needs realism, and predictions cannot be made for this type of study. Certainly,” he concluded optimistically, “the progress made with stem cells in the past 12 years since their discovery is a great cause for hope”.

Reblog this post [with Zemanta]

Incoming search terms:

stem cells transplant for thalassemia.

U.S. Army Gives $700,000 to Stem Cell Therapy Research

The U.S. Army Medical Research and Materiel Co...
Image via Wikipedia

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that it has been awarded a $700,000 contract from the U.S. Army Medical Research and Materiel Command, Telemedicine and Advanced Technology Research Center (USAMRMC-TATRC) under U.S. Army Medical Research Acquisition Activity contract number: (W81XWH-10-2-0039).

This contract is for the purpose of evaluating the use of topically applied bone marrow-derived adult mesenchymal stem cells (MSCs) for rapid wound healing. The Company previously announced that this funding was included in the Department of Defense FY09 Appropriations Bill and will begin receiving funds to initiate the program in 2010.

“NeoStem is thrilled to have the United States Government’s support to advance our technology and is honored to become part of TATRC’s regenerative medicine portfolio. It is our goal with this important project to leverage adult stem cell technology to help our soldiers avoid amputations and immobilization from injuries that they may sustain while fighting for our country.

Continue reading

Stem Cells from Japan Used in Transplant in Pisa

Location of Tuscany in Italy
Image via Wikipedia

An extraordinary operation was performed in Pisa when a 5 year old boy from Tuscany with acute lymphoblastic leukemia underwent a bone marrow transplant last night with stem cells explanted from a patient in Japan where the only donor with virological and histological compatibility was found after a 6-7 month worldwide search. The stem cell infusion was performed at the Pediatric Oncohematology Unit at the University of Pisa Hospital directed by Claudio Favre, one of the seven internationally accredited centers collaborating with the national Italian Bone Marrow Donor Registry (IBMDR).

The infusion procedure, reported the hospital in Pisa, lasted about 7 hours and the child is well. Doctors hope that intensive chemotherapy along with total body irradiation last week and the newly implanted stem cells will repopulate the boy’s bone marrow and allow him to fight the disease.

The hospital underlined that what took place between Italy and Japan was a true marathon of solidarity including, in addition to both hospitals and medical teams in both Pisa and Tenri (Southeast Japan), the Italian Civil Protection Service, which provided the airplane that flew from Osaka to Pisa allowing the stem cells to be transported by the only compatible donor found out of 12 million in the entire world.

Continue reading

Incoming search terms:

dr george cotsarelis hair loss.

Cord Blood America: Company is Ready to Expand and Grow

BioMedReports: There has been some talk about the upcoming opening of your new state-of-the-art facility. Can you tell us about that?

CEO Matthew L. Schissler: We always try to focus on three core goals and in 2010 we are opening our new state of the art laboratory. One of those three core goals is the diversification of revenue streams. Not only will we have our own organic growth engine, by processing and storing for our own company, but we recently entered into a letter of agreement to process and store for another very successful stem cell company. That’s going to be the flavor for 2010 and onward- diversification of revenue streams by using our new facility to its full capacity. The other goal is continued growth- like we saw mention of when we announced in late 2009 when we signed an agreement with a national labor association, Blue Cross and Blue Shield Association. That’s how we’ll grow some more, through the insurance companies. And finally, we’re going to be very focused on acquisitions. In fact, I’ll tell you that in 2010 we have a voracious appetite for acquisitions. With the economy the way it is, a lot of stem cell companies are struggling and we’ve been very fortunate to have our company go in the right direction by reducing debt and raising capital. We feel it’s a very good time for us to make some acquisitions and so we’re going to be very focused on that this year.

BioMedReports: So I would imagine that these acquisitions are somehow related to the goal of increasing your revenue streams in some way?

CEO Matthew L. Schissler: The overall goal in our mission statement is to not only become the world’s number one most respected stem cell company but also to be the largest as well. As we say in our mission statement, the world’s globally dominant stem cell storage company and so, those acquisitions will be in related fields, but I can’t say too much but it’s all about cryogenic preservation of stem cells and other forms of biologics.

Continue reading